Ekow Essien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ekow Essien has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Samuel B. Governor
Department of Cardiology, St. John’s Episcopal Hospital, Far Rockaway, NY, USA
3 shared publications Abena Agyekum
Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, USA
2 shared publications- Abena Agyekum
Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
2 shared publications - Abraham Carboo
Department of Medicine, Yale-Waterbury Hospital, Waterbury, Connecticut, United States
2 shared publications Gloria Amoako
Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, USA
2 shared publications- Gloria Kyem
Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
2 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity
Background: Adults with serious mental illness (SMI), type 2 diabetes, and obesity have elevated cardiovascular risk. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have established cardiometabolic benefits in the general population, but their effects in SMI are unclear. We evaluated whether GLP‐1RA use was associated with lower risks of incident myocardial infarction (MI), heart failure (HF), and all‐cause death. Methods: This was a retrospective propensity score–matched cohort study of 218 043 adults with SMI, type 2 diabetes, obesity, and active antipsychotic or antidepressant medications in the TriNetX database (73 health care organizations). Outcomes were incident MI, HF, and all‐cause death at 1 and 3 years. The primary exposure was GLP‐1RA use versus nonuse; secondary analyses examined semaglutide or tirzepatide. Exploratory analyses evaluated sex, race, and sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use. Results: GLP‐1RA use was associated with lower risks of incident MI, HF, and all‐cause death. Risk differences at 1 and 3 years were −0.007 and −0.010 for MI, −0.011 and −0.018 for HF, and −0.039 and −0.065 for death (all P P <0.001). Findings were directionally consistent after accounting for sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use. Conclusions: Adults with treated SMI, type 2 diabetes, and obesity using GLP‐1RAs, particularly semaglutide or tirzepatide, had significantly reduced 1‐ and 3‐year risks of incident MI, HF, and all‐cause death versus nonusers. These pooled associations should be interpreted in the context of SMI's clinical heterogeneity and the limitations of administrative case ascertainment.
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Open AccessGlucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity
Background: Adults with serious mental illness (SMI), type 2 diabetes, and obesity have elevated cardiovascular risk. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have established cardiometabolic benefits in the general population, but their effects in SMI are unclear. We evaluated whether GLP‐1RA use was associated with lower risks of incident myocardial infarction (MI), heart failure (HF), and all‐cause death. Methods: This was a retrospective propensity score–matched cohort study of 218 043 adults with SMI, type 2 diabetes, obesity, and active antipsychotic or antidepressant medications in the TriNetX database (73 health care organizations). Outcomes were incident MI, HF, and all‐cause death at 1 and 3 years. The primary exposure was GLP‐1RA use versus nonuse; secondary analyses examined semaglutide or tirzepatide. Exploratory analyses evaluated sex, race, and sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use. Results: GLP‐1RA use was associated with lower risks of incident MI, HF, and all‐cause death. Risk differences at 1 and 3 years were −0.007 and −0.010 for MI, −0.011 and −0.018 for HF, and −0.039 and −0.065 for death (all P P <0.001). Findings were directionally consistent after accounting for sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use. Conclusions: Adults with treated SMI, type 2 diabetes, and obesity using GLP‐1RAs, particularly semaglutide or tirzepatide, had significantly reduced 1‐ and 3‐year risks of incident MI, HF, and all‐cause death versus nonusers. These pooled associations should be interpreted in the context of SMI's clinical heterogeneity and the limitations of administrative case ascertainment.
- Open Access
- 1 October 2026
- Published by Wolters Kluwer Health in International Journal of Diabetes and Technology
- Vol. 5 (4) , 176-182
Fibrinogen as a Prognostic Biomarker in Patients with Type 2 Diabetes with Coronary Artery Disease: A Propensity-matched Study
Background: Elevated fibrinogen is associated with increased cardiovascular risk; however, its prognostic significance in patients with coexisting type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) is not well established. Aim: The aim is to evaluate whether elevated fibrinogen levels are independently associated with increased 5-year risk of all-cause mortality and major cardiovascular and renal events in patients with T2DM and established CAD, using a large propensity-matched real-world cohort. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network (130 healthcare organizations). Adults aged 18–90 years with T2DM and CAD were stratified by fibrinogen level into high (≥401 mg/dL) and low (≤400 mg/dL) groups. After propensity score matching, 92,684 patients were included in each cohort and followed for 5 years. The primary outcome was all-cause mortality. Secondary outcomes included heart failure, acute kidney injury (AKI), ventricular tachycardia, cerebrovascular disease, pulmonary embolism, acute myocardial infarction (AMI), and chronic kidney disease (CKD). Results: The high-fibrinogen cohort had greater 5-year mortality compared with the low-fibrinogen cohort (36.6% vs. 30.7%; hazard ratio [HR]: 1.267, 95% confidence interval [CI]: 1.247–1.287; P < 0.001). Elevated fibrinogen was also associated with higher risks of heart failure (HR: 1.119), AKI (HR: 1.242), cerebrovascular disease (HR: 1.127), AMI (HR: 1.204), and CKD (HR: 1.186) (all P < 0.001). Conclusion: Among patients with T2DM and CAD, elevated fibrinogen independently predicts increased mortality and major cardiovascular and renal events, supporting its role as a prognostic biomarker in this high-risk population.
- 1 October 2026
- Published by Wolters Kluwer Health in International Journal of Diabetes and Technology
- Vol. 5 (4) , 176-182
Open AccessFibrinogen as a Prognostic Biomarker in Patients with Type 2 Diabetes with Coronary Artery Disease: A Propensity-matched Study
Background: Elevated fibrinogen is associated with increased cardiovascular risk; however, its prognostic significance in patients with coexisting type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) is not well established. Aim: The aim is to evaluate whether elevated fibrinogen levels are independently associated with increased 5-year risk of all-cause mortality and major cardiovascular and renal events in patients with T2DM and established CAD, using a large propensity-matched real-world cohort. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network (130 healthcare organizations). Adults aged 18–90 years with T2DM and CAD were stratified by fibrinogen level into high (≥401 mg/dL) and low (≤400 mg/dL) groups. After propensity score matching, 92,684 patients were included in each cohort and followed for 5 years. The primary outcome was all-cause mortality. Secondary outcomes included heart failure, acute kidney injury (AKI), ventricular tachycardia, cerebrovascular disease, pulmonary embolism, acute myocardial infarction (AMI), and chronic kidney disease (CKD). Results: The high-fibrinogen cohort had greater 5-year mortality compared with the low-fibrinogen cohort (36.6% vs. 30.7%; hazard ratio [HR]: 1.267, 95% confidence interval [CI]: 1.247–1.287; P < 0.001). Elevated fibrinogen was also associated with higher risks of heart failure (HR: 1.119), AKI (HR: 1.242), cerebrovascular disease (HR: 1.127), AMI (HR: 1.204), and CKD (HR: 1.186) (all P < 0.001). Conclusion: Among patients with T2DM and CAD, elevated fibrinogen independently predicts increased mortality and major cardiovascular and renal events, supporting its role as a prognostic biomarker in this high-risk population.
- Open Access
- 11 June 2026
- Published by Turkiye Kalp Ve Saglik Vakfi Iktisadi Isletmesi in Journal of Updates in Cardiovascular Medicine
- Vol. 14 (2) , 43-51
Association between Glycemic Control and Adverse Outcomes in Atrial Fibrillation: Evidence from a Large Real-world Cohort
Association between Glycemic Control and Adverse Outcomes in Atrial Fibrillation: Evidence from a Large Real-world Cohort - Journal of Updates in Cardiovascular Medicine
- 11 June 2026
- Published by Turkiye Kalp Ve Saglik Vakfi Iktisadi Isletmesi in Journal of Updates in Cardiovascular Medicine
- Vol. 14 (2) , 43-51
Open AccessAssociation between Glycemic Control and Adverse Outcomes in Atrial Fibrillation: Evidence from a Large Real-world Cohort
Association between Glycemic Control and Adverse Outcomes in Atrial Fibrillation: Evidence from a Large Real-world Cohort - Journal of Updates in Cardiovascular Medicine
- Open Access
- 1 June 2026
- Published by Georg Thieme Verlag KG in Sleep Science
- Vol. 19 (02) , 001-009
C-Reactive Protein as a Predictor of Cardiovascular Events and Mortality in Obstructive Sleep Apnea: A Propensity-Matched Analysis Using the TriNetX Research Network
Obstructive sleep apnea (OSA) increases cardiovascular disease risk through systemic inflammation, particularly through elevated C-reactive protein (CRP). This study investigated whether CRP stratification predicts mortality and cardiovascular events in OSA patients. We conducted a retrospective cohort analysis using the TriNetX Research Network, encompassing electronic health records from 130 healthcare institutions. Adults (ages 18–90 years) with OSA were stratified by CRP concentration: elevated (≥ 3.0 mg/L) versus low (≤ 2.9 mg/L). After propensity score matching for demographics and comorbidities, 240,727 participants per cohort were followed for five years. Primary outcome was all-cause mortality; secondary outcomes included cardiovascular events, arrhythmias, and acute kidney injury. Elevated CRP was associated with significantly higher all-cause mortality (11.3% versus 7.0%; HR 1.695, 95% CI 1.662–1.727; p < 0.001). The elevated CRP group demonstrated heightened cardiovascular risk: cardiogenic shock (1.0% versus 0.5%; HR 2.003), heart failure (9.8% versus 6.5%; HR 1.594), pulmonary hypertension (4.9% versus 3.4%; HR 1.508), and acute kidney injury (11.0% versus 6.4%; HR 1.825), all p < 0.001. Arrhythmic complications were also increased: atrial fibrillation/flutter (6.3% versus 4.8%; HR 1.372) and ventricular tachycardia (2.3% versus 1.8%; HR 1.388), both p < 0.001. Elevated CRP constitutes a robust predictor of mortality and cardiovascular morbidity in OSA populations. Assessment of inflammatory biomarkers may enhance risk stratification, informing intensified monitoring and targeted therapeutic interventions.
- 1 June 2026
- Published by Georg Thieme Verlag KG in Sleep Science
- Vol. 19 (02) , 001-009
Open AccessC-Reactive Protein as a Predictor of Cardiovascular Events and Mortality in Obstructive Sleep Apnea: A Propensity-Matched Analysis Using the TriNetX Research Network
Obstructive sleep apnea (OSA) increases cardiovascular disease risk through systemic inflammation, particularly through elevated C-reactive protein (CRP). This study investigated whether CRP stratification predicts mortality and cardiovascular events in OSA patients. We conducted a retrospective cohort analysis using the TriNetX Research Network, encompassing electronic health records from 130 healthcare institutions. Adults (ages 18–90 years) with OSA were stratified by CRP concentration: elevated (≥ 3.0 mg/L) versus low (≤ 2.9 mg/L). After propensity score matching for demographics and comorbidities, 240,727 participants per cohort were followed for five years. Primary outcome was all-cause mortality; secondary outcomes included cardiovascular events, arrhythmias, and acute kidney injury. Elevated CRP was associated with significantly higher all-cause mortality (11.3% versus 7.0%; HR 1.695, 95% CI 1.662–1.727; p < 0.001). The elevated CRP group demonstrated heightened cardiovascular risk: cardiogenic shock (1.0% versus 0.5%; HR 2.003), heart failure (9.8% versus 6.5%; HR 1.594), pulmonary hypertension (4.9% versus 3.4%; HR 1.508), and acute kidney injury (11.0% versus 6.4%; HR 1.825), all p < 0.001. Arrhythmic complications were also increased: atrial fibrillation/flutter (6.3% versus 4.8%; HR 1.372) and ventricular tachycardia (2.3% versus 1.8%; HR 1.388), both p < 0.001. Elevated CRP constitutes a robust predictor of mortality and cardiovascular morbidity in OSA populations. Assessment of inflammatory biomarkers may enhance risk stratification, informing intensified monitoring and targeted therapeutic interventions.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5
Comparative Outcomes of Catheter-Directed Thrombectomy Versus Catheter-Directed Thrombolysis in Obese Patients With Pulmonary Embolism: A Propensity-Matched Analysis Using the TriNetX Global Health Research Network
Essien E, et al. J Cardiovasc Interv. 2025 Aug;5:e2. https://doi.org/10.54912/jci.2025.0029
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5
Open AccessComparative Outcomes of Catheter-Directed Thrombectomy Versus Catheter-Directed Thrombolysis in Obese Patients With Pulmonary Embolism: A Propensity-Matched Analysis Using the TriNetX Global Health Research Network
Essien E, et al. J Cardiovasc Interv. 2025 Aug;5:e2. https://doi.org/10.54912/jci.2025.0029